Two senior physicians who co-founded Fullerton Healthcare Corporation (FHC) have been penalised with combined fines totalling S$160,000 for orchestrating a scheme involving falsified entertainment expense claims, a Singapore court ruled on July 10. Daniel Chan Pai Sheng and Michael Tan Kim Song, both aged 52, were found guilty of falsification of accounts relating to expenses that exceeded S$211,000 in inflated charges. Notably, neither man benefited financially from the offences; instead, the entire scheme was designed to channel funds toward Collin Chiew, a third party whose own case remains under adjudication.
Chan received the harsher penalty of S$135,000 after admitting to five counts of falsification of accounts, while Tan accepted a S$25,000 fine following his guilty plea to a single charge. The disparity in penalties reflects the extent of their respective involvement in the scheme. Chan's falsified claims totalled more than S$336,000 when legitimate expenses amounted to approximately S$125,000, creating an inflated variance of over S$211,000. Tan's involvement centred on a single claim valued at around S$82,000, whereas genuine costs stood at just over S$42,000, resulting in an inflation of nearly S$40,000 that contributed to the broader falsification pattern.
The prosecution had initially pursued graft-related charges against both men; however, Deputy Public Prosecutors Jonathan Tan and Ashley Chin subsequently applied for a discharge not amounting to acquittal for those allegations, citing prosecutorial discretion. District Judge Paul Quan granted this application on the same day. This particular legal mechanism means that while the graft accusations have been formally dismissed for now, they remain available for prosecution should new evidence or information surface in future proceedings. The decision to pursue falsification charges instead suggests that authorities prioritised demonstrable account manipulation over broader corruption allegations that may have been more complex to establish beyond reasonable doubt.
Chiew, aged 58, served as chief executive of insurance broker Aon Singapore between January 2015 and July 2018, a position that connected him to the business environment in which FHC operated. Court documents did not clarify whether Chiew ultimately received the S$211,000 in question. Around 2012, Tan and Chan encountered Chiew while seeking business opportunities, establishing a relationship that would later become central to the scheme. By 2015, Chiew approached Chan requesting financial assistance, citing personal needs related to his children's education and residential mortgage obligations. Rather than declining, Chan discussed the request with Tan, setting in motion a coordinated plan to extract funds from their company through fraudulent means.
The mechanics of the falsification scheme reveal considerable sophistication and deliberate planning. Beginning in 2015, Chan undertook regular business trips to Hong Kong, visiting approximately twice monthly to support FHC's operations in that market. Before departing Singapore, he would instruct David Sin, the third FHC co-founder, to prepare inflated or entirely fabricated KTV receipts—entertainment venue invoices that would serve as ostensible justification for expense claims. A fourth conspirator, Tei Chu Pink, aged 46, handled the actual creation of these false documents. Upon arrival in Hong Kong, Chan would attend these venues with Sin and Tei, ostensibly to meet potential investors. However, the manner in which payments were handled demonstrated the fraudulent intent underlying these gatherings. On numerous occasions, Chan made only nominal cash or credit card payments at the establishments, or paid nothing whatsoever, yet later submitted the inflated receipts as legitimate business expenses.
Once back in Singapore, Chan orchestrated the distribution of these falsified receipts to relevant personnel within FHC and its subsidiary Fullerton Health China, ensuring they entered the standard reimbursement pipeline. These individuals processed the claims systematically, converting fraudulent documentation into actual fund transfers. Crucially, Tan possessed knowledge of many of these claims, implying tacit approval from the co-founder and director level. Prosecutors established that a significant portion of the funds ultimately obtained through this scheme were specifically allocated to provide the financial assistance that Chiew had initially requested, linking the elaborate falsification apparatus directly to the original assistance request.
In August 2025, David Sin, the third FHC co-founder, pleaded guilty to six counts of falsification of accounts and received an identical S$160,000 fine to Chan's penalty. Sin's involvement appeared more extensive than Tan's limited participation, though less comprehensive than Chan's orchestration of the entire operation. Both Chan and Tan have since relinquished their respective positions within the company structure—Chan as president of Fullerton Health China and Tan as director of Fullerton Healthcare Group, both subsidiaries of FHC. This removal from operational roles effectively distances them from ongoing business activities, though it remains unclear whether additional corporate governance reforms or oversight mechanisms have been implemented within the organisation.
FHC, established through the co-founders' business vision, operated as an investment holding company with diversified subsidiaries. Fullerton Healthcare Group, which Tan and Chan had co-founded a decade earlier in 2010, provided medical services through an extensive network of physicians and healthcare specialists while also offering clients assistance with insurance claim processing. This dual healthcare and insurance interface positioned the company within Singapore's regulated healthcare and financial services ecosystems, making the falsification of expense claims particularly problematic from a compliance and governance perspective. The breadth of FHC's operations and its subsidiary network raise questions about the adequacy of internal controls and audit procedures that might have prevented or detected such systematic falsification.
The case underscores vulnerabilities in expense management systems, particularly in businesses operating across multiple jurisdictions where oversight becomes more challenging. Entertainment expenses claimed in relation to business development activities in Hong Kong created plausible deniability for legitimate purposes, yet the systematic pattern of inflated or non-existent payments reveals intentional deception rather than administrative error or aggressive accounting interpretations. For Malaysian business operators and investors monitoring regional corporate governance trends, the case demonstrates that even well-established healthcare enterprises with sophisticated operations remain susceptible to insider fraud when adequate separation of duties and independent verification mechanisms are insufficient.
Beyond the immediate penalties imposed, the case raises broader questions about accountability within Southeast Asian business structures. The initial pursuit of corruption charges, later discharged at prosecutorial discretion, suggests that authorities encountered evidentiary challenges despite apparent circumstantial evidence of systematic fraud. The decision to proceed with falsification charges instead represents a narrower but more prosecutable theory of liability. For corporate compliance officers and boards across the region, the case illustrates the criticality of robust internal audit functions, particularly regarding entertainment and travel expenses that frequently attract regulatory scrutiny in Singapore's stringent regulatory environment.
The implications for Malaysian business practice are significant. While Singapore maintains relatively advanced regulatory infrastructure and enforcement capacity, similar schemes might persist longer in jurisdictions with less developed investigative agencies or audit oversight. Companies with cross-border operations, particularly those traversing Southeast Asia, should recognise that inconsistent governance standards across subsidiaries create opportunities for fraud. The Fullerton Healthcare case demonstrates that physician-founders with business acumen can orchestrate sophisticated schemes that evade detection for extended periods, challenging assumptions that professionals naturally maintain ethical standards in financial matters.
Looking forward, the case may influence how Singapore's financial regulators and professional bodies approach oversight of healthcare enterprises and how insurance intermediaries like Aon Singapore are evaluated regarding their executives' external activities. For regional businesses, the critical lesson involves implementing controls that function regardless of the integrity of senior personnel, including mandatory independent approval for all entertainment and discretionary expenses above defined thresholds, regular external audit verification of supporting documentation, and periodic rotation of approval responsibilities. The S$160,000 fines, while substantial, represent only a fraction of the falsified amounts, potentially serving as insufficient deterrent without accompanying reputational damage and loss of operational authority within the healthcare sector.
